文献速递心脑血管急症

质量改进干预对印度急性心肌梗死患者临床结局的影响:ACS QUIK随机临床试验

Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01
一句话结论在印度喀拉拉邦63家医院中,与常规护理相比,使用本地化质量改进工具包并未降低急性心肌梗死患者30天主要不良心血管事件复合终点。

该研究为集群随机阶梯楔形临床试验,纳入印度喀拉拉邦63家医院连续就诊的急性心肌梗死患者共21374例,随机分为质量改进工具包组(干预组,n=11308)和常规护理组(对照组,n=10066)。工具包包括审计与反馈、检查清单、患者教育材料、与急诊心血管护理的联动及质量改进培训。主要终点为30天全因死亡、再梗死、卒中或大出血的复合终点,干预组发生率为5.3%,对照组为6.4%,校正后差异无统计学意义(校正风险差-0.09%,95%CI -1.32%至1.14%;校正OR 0.98,95%CI 0.80-1.21)。干预组药物使用(包括再灌注)率更高,但对戒烟咨询无影响,未报告意外不良事件。

要点

  • 在印度喀拉拉邦63家医院中,质量改进工具包未能显著降低急性心肌梗死患者30天主要不良心血管事件复合终点(干预组5.3% vs 对照组6.4%,校正OR 0.98,95%CI 0.80-1.21)。
  • 干预组药物使用率(包括再灌注)高于对照组,但戒烟咨询率无差异。
  • 该工具包包括审计与反馈、检查清单、患者教育材料、与急诊心血管护理联动及质量改进培训。
  • 研究结论认为需进一步研究以理解为何质量改进干预未能显示出疗效。

适用人群与场景

  • 印度喀拉拉邦63家医院连续就诊的急性心肌梗死患者,平均年龄60.6岁(SD 12.0),男性16183例(76%),ST段抬高型心肌梗死13689例(64%)。

处置流程与药物剂量

  • 干预组医院采用质量改进工具包,包括审计与反馈、检查清单、患者教育材料、与急诊心血管护理的联动及质量改进培训。

研究设计与关键结果

  • 研究类型为集群随机阶梯楔形临床试验,纳入63家医院,21374例患者随机(干预组11308例,对照组10066例),21079例(99%)完成试验。
  • 主要复合终点(30天全因死亡、再梗死、卒中或大出血)干预组发生率5.3%,对照组6.4%;校正风险差-0.09%(95%CI -1.32%至1.14%),校正OR 0.98(95%CI 0.80-1.21),差异无统计学意义。
  • 干预组药物使用(包括再灌注)率高于对照组,但戒烟咨询无差异。
  • 未报告意外不良事件。

证据类型、等级与局限

  • 证据类型:集群随机阶梯楔形临床试验。
  • 局限:原文未报告局限性(结论指出需进一步研究以理解缺乏疗效的原因)。

对床旁实践的改变

  • 作者认为,在印度喀拉拉邦急性心肌梗死患者中,与常规护理相比,使用质量改进干预未降低30天主要不良心血管事件复合终点,需进一步研究以理解缺乏疗效的原因。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Wide heterogeneity exists in acute myocardial infarction treatment and outcomes in India.

OBJECTIVE: To evaluate the effect of a locally adapted quality improvement tool kit on clinical outcomes and process measures in Kerala, a southern Indian state.

DESIGN, SETTING, AND PARTICIPANTS: Cluster randomized, stepped-wedge clinical trial conducted between November 10, 2014, and November 9, 2016, in 63 hospitals in Kerala, India, with a last date of follow-up of December 31, 2016. During 5 predefined steps over the study period, hospitals were randomly selected to move in a 1-way crossover from the control group to the intervention group. Consecutively presenting patients with acute myocardial infarction were offered participation.

INTERVENTIONS: Hospitals provided either usual care (control group; n = 10 066 participants [step 0: n = 2915; step 1: n = 2649; step 2: n = 2251; step 3: n = 1422; step 4; n = 829; step 5: n = 0]) or care using a quality improvement tool kit (intervention group; n = 11 308 participants [step 0: n = 0; step 1: n = 662; step 2: n = 1265; step 3: n = 2432; step 4: n = 3214; step 5: n = 3735]) that consisted of audit and feedback, checklists, patient education materials, and linkage to emergency cardiovascular care and quality improvement training.

MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of all-cause death, reinfarction, stroke, or major bleeding using standardized definitions at 30 days. Secondary outcomes included the primary outcome's individual components, 30-day cardiovascular death, medication use, and tobacco cessation counseling. Mixed-effects logistic regression models were used to account for clustering and temporal trends.

RESULTS: Among 21 374 eligible randomized participants (mean age, 60.6 [SD, 12.0] years; n = 16 183 men [76%] ; n = 13 689 [64%] with ST-segment elevation myocardial infarction), 21 079 (99%) completed the trial. The primary composite outcome was observed in 5.3% of the intervention participants and 6.4% of the control participants. The observed difference in 30-day major adverse cardiovascular event rates between the groups was not statistically significant after adjustment (adjusted risk difference, -0.09% [95% CI, -1.32% to 1.14%]; adjusted odds ratio, 0.98 [95% CI, 0.80-1.21]). The intervention group had a higher rate of medication use including reperfusion but no effect on tobacco cessation counseling. There were no unexpected adverse events reported.

CONCLUSIONS AND RELEVANCE: Among patients with acute myocardial infarction in Kerala, India, use of a quality improvement intervention compared with usual care did not decrease a composite of 30-day major adverse cardiovascular events. Further research is needed to understand the lack of efficacy.

TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02256657.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Huffman MD, Mohanan PP, Devarajan R, et al. Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial. JAMA. 2018. PMID: 29450524. doi:10.1001/jama.2017.21906

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。